Construction and delivery of gene therapy vector containing soluble TNFalpha receptor-IgGFc fusion gene for the treatment of allergic rhinitis

Tumor necrosis factor alpha plays primary role in the pathogenesis of inflammatory diseases. TNFalpha is essential for antigen-specific IgE production and for the induction of Th2-type cytokines. The lack of TNFalpha inhibited the development of allergic rhinitis. In this study, the chimeric gene of...

Full description

Saved in:
Bibliographic Details
Published in:Cytokine (Philadelphia, Pa.) Pa.), 2006-12, Vol.36 (5-6), p.296-304
Main Authors: He, Jie, Wang, Tong, Yao, Lihong, Chen, Aijun, Zhou, Bing, Yu, Hong, Jia, Runqing, Cheng, Congsheng, Huan, Lifang, Zhang, Zhiqing
Format: Article
Language:English
Subjects:
Animals
Disease Models, Animal
Genetic Therapy
Herpesvirus 4, Human - genetics
Humans
Immunoglobulin Fc Fragments - genetics
Immunoglobulin G - genetics
Male
Mice
Mice, Inbred BALB C
Nasal Mucosa - pathology
Receptors, Tumor Necrosis Factor - genetics
Recombinant Proteins - genetics
Respiratory Hypersensitivity - pathology
Respiratory Hypersensitivity - therapy
Rhinitis - pathology
Rhinitis - therapy
Tumor Necrosis Factor-alpha - metabolism
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor necrosis factor alpha plays primary role in the pathogenesis of inflammatory diseases. TNFalpha is essential for antigen-specific IgE production and for the induction of Th2-type cytokines. The lack of TNFalpha inhibited the development of allergic rhinitis. In this study, the chimeric gene of soluble TNF receptor and IgGFc fragment (sTNFR-IgGFc) was cloned into the EBV-based plasmid pGEG. When the plasmid pGEG.sTNFR-IgGFc was transferred to endothelium cell, a considerable expression of the sTNFR-IgGFc fusion protein was detected. Moreover, the expression product in the supernatant could antagonize the cytolytic activity of TNFalpha on L929 cells. Then the plasmid was delivered into nasal mucosa of allergic rhinitis mice to determine its effect on this animal model. Results showed that symptoms in treated group were improved. Pathological examination showed the numbers of eosinophil, mast cell and IL-5(+) cells in treated groups were reduced compared with placebo group. These data showed that pGEG.sTNFR-IgGFc expression plasmid is potential for the treatment of allergic rhinitis, and suggest that the antagonist of TNFalpha may provide a new approach for the treatment of allergic rhinitis.
ISSN:1043-4666